Setting the stage for a battle with rival Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO) reported data this week from a late-stage trial of its oral formulation of semaglutide, a medication for people with Type II diabetes.
The GLP-1 agonist is traditionally administered via injection. Both insulin-makers have approved versions of the injectable semaglutide, but Novo Nordisk is the first to take its oral formulation into large clinical studies.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk touts promising results from late-stage trial of oral diabetes med appeared first on MassDevice.